| Literature DB >> 24531557 |
Anchalee Avihingsanon1, Reshmie A Ramautarsing2, Gompol Suwanpimolkul3, Ploenchan Chetchotisakd4, Chureeratana Bowonwatanuwong5, Supunnee Jirajariyavej6, Patcharee Kantipong7, Hutsaya Tantipong5, June Pirapon Ohata8, Chusana Suankratay3, Kiat Ruxrungtham2, David M Burger9.
Abstract
Ergotism is a toxic condition resulting from overexposure to the ergot compounds produced by various fungi of the genus Claviceps. Traditionally, such exposure was due to ingestion of infected grains, but long-term or excessive use of medications containing ergot derivatives or drug-drug interactions between these medications can result in ergotism. Ergotamine, typically used to treat migraine, has less than 5% bioavailability due to extensive first-pass metabolism by cytochrome P450 3A4 (CYP3A4). Concurrent intake of ergotamine and strong CYP3A4 inhibitors, such as the HIV protease inhibitors (PIs), can lead to clinical ergotism. A total of 13 cases of clinical ergotism in HIV-infected patients has been published since 1997 (most recently reviewed by Frohlich et al).Entities:
Mesh:
Substances:
Year: 2014 PMID: 24531557 PMCID: PMC6148849
Source DB: PubMed Journal: Top Antivir Med ISSN: 2161-5853